Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

raltegravir potassium

Known as: N-[(4-Fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-[1-methyl-1-[[ (5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino]ethyl]-6-oxo-4-pyrimidinecarboxamide Monopotassium Salt, Potassium, Raltegravir, Raltegravir Potassium [Chemical/Ingredient] 
The orally bioavailable potassium salt of a human immunodeficiency virus (HIV) integrase strand transfer inhibitor (HIV-1 INSTI) with HIV-1 antiviral… Expand
National Institutes of Health

Related topics

Related topics

14 relations

Broader (3)

Anti-HIV AgentsHIV Integrase Inhibitorsraltegravir
In Bloodagonistsanalogs & derivativesantagonists & inhibitors
Expand

Narrower (2)

IsentressMK 0518

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Spectrophotometric Estimation of Raltegravir Potassium in Tablets
Ultra violet spectrophotometric estimation of the raltegravir potassium, an integrase inhibitor antiretroviral agent was… Expand
  • table 1
  • table 2
  • figure 2
  • figure 1
  • table 3
2014
2014
DEVELOPMENT AND VALIDATION OF RP- HPLC METHOD FOR DETERMINATION OF RALTEGRAVIR AND ITS IMPURITIES IN BULK DRUG AND DOSAGE FORMS
A simple, sensitive, rapid high performance liquid chromatography methodhas been developed for estimation of related compounds… Expand
  • figure 6
2013
2013
Simple Spectrophotometric Method for Estimation of Raltegravir Potassium in Bulk and Pharmaceutical Formulations
A simple, rapid, precise, and economical spectrophotometric method has been developed for quantitative analysis of Raltegravir… Expand
  • figure 3
  • table 3
  • table 6
2012
2012
VALIDATED STABILITY-INDICATING UPLC ASSAY METHOD A ND DEGRADATION BEHAVIOR OF RALTEGRAVIR POTASSIUM
 
2011
2011
Development and Validation of RP-HPLC and HPTLC Chromatographic Methods of Analysis for the Quantitative Estimation of Raltegravir Potassium in Pharmaceutical Dosage Form
A high performance liquid chromatography and high performance thin layer liquid chromatography method were developed and… Expand
2011
2011
Reverse Phase - High Performance Liquid Chromatography and Ultra Violet Spectrophotometric Method for The Estimation of Raltegravir Potassium in Bulk and in Tablet Dosage form
A High Performance Liquid Chromatographic (method A) and Ultra Violet spectrophotometric (method B) method were developed and… Expand
  • figure 1
  • figure 2
  • table 7
  • table 9
2011
2011
REVERSE PHASE –HIGH PERFORMANCE LIQUID CHROMATOGRAPHY AND ULTRA VIOLET SPECTROPHOTOMETRIC METHOD FOR THE ESTIMATION OF RALTEGRAVIR POTASSIUM IN BULK
A High Performance Liquid Chromatographic (method A) and Ultra Violet spectrophotometric (method B) method were developed and… Expand
2010
2010
Gateways to clinical trials.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… Expand
2009
2009
Process for preparing amorphous raltegravir potassium
Process for preparing raltegravir potassium in amorphous form comprising: a. raltegravir potassium stirring in water; b. removing… Expand
2008
2008
A polar radical pair pathway to assemble the pyrimidinone core of the HIV integrase inhibitor raltegravir potassium.
The UN and WHO currently estimate that 40 million people are living with HIV/AIDS worldwide. Combination therapies using reverse… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE